Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 2/20 | 0.41 |
| ▸ | MAX | P61244 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29231875 | 0.89 | L3MBTL1 (0.43) | ALDH1A1L3MBTL1KDM4EHPGDHSD17B10 | |
| SCHEMBL29231911 | 0.88 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KDM4EHPGDHSD17B10 | |
| SCHEMBL30106811 | 0.88 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KDM4EHPGDHSD17B10 | |
| SCHEMBL30945383 | 0.88 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KDM4EHPGDHSD17B10 | |
| SCHEMBL21515059 | 0.83 | L3MBTL1 (0.48) | ALDH1A1L3MBTL1KDM4EHPGDHSD17B10 | |
| SCHEMBL23005210 | 0.81 | FPR2 (0.51) | KDM4EHPGDMYCMAX | |
| SCHEMBL23005209 | 0.81 | FPR2 (0.51) | KDM4EHPGDMYCMAX | |
| SCHEMBL9782435 | 0.79 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1KDM4EHPGDHSD17B10 | |
| SCHEMBL9782445 | 0.79 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1KDM4EHPGDHSD17B10 | |
| SCHEMBL21515058 | 0.78 | FPR2 (0.47) | ALDH1A1L3MBTL1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2025-07-15 | — | — | US | disclosed |
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2023-04-13 | — | — | US | disclosed |
| US-11504368-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2022-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11504368-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | ALDH1A1 199/4885L3MBTL1 4321/4885KDM4E 2274/4885 |
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | ALDH1A1 254/4885L3MBTL1 4348/4885KDM4E 2175/4885 |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | ALDH1A1 254/4885L3MBTL1 4348/4885KDM4E 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.